IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jabs, D. A.
Right arrow Articles by Prendergast, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jabs, D. A.
Right arrow Articles by Prendergast, R. A.

Investigative Ophthalmology & Visual Science, Vol 37, 246-250, Copyright © 1996 by Association for Research in Vision and Ophthalmology

ARTICLES AND REPORTS

Paradoxic effect of anti-CD4 therapy on lacrimal gland disease in MRL/Mp-lpr/lpr mice

DA Jabs, WH Burns and RA Prendergast
Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

PURPOSE. MRL/Mp-lpr/lpr mice (MRL/lpr) spontaneously develop lacrimal gland inflammatory lesions and are a model for the human disease Sjogren's syndrome. Therapy with monoclonal antibodies (mAb) to CD4 ameliorates the autoimmune renal, vasculitic, and intraocular inflammatory lesions in MRL/lpr mice. The effect of anti-CD4 mAb therapy on lacrimal gland immunopathology was evaluated. METHODS. From 1 to 5 months of age, MRL/lpr mice were treated with weekly intraperitoneal injections of 2 mg anti-CD4 mAb, after which they were killed and their lacrimal glands were removed for histologic evaluation and immunocytochemistry. Control mice were administered weekly intraperitoneal injections of either saline or normal rat immunoglobulin. RESULTS. Anti-CD4 mAb treatment produced no reduction in lacrimal gland inflammation but did change its morphology. In control mice, there were multiple sharply delineated foci of inflammatory cells in the lacrimal gland, whereas in anti-CD4 mAb- treated mice, there was a more diffuse inflammation surrounding ill- defined foci that spread throughout the gland. Immunocytochemistry revealed that in control mice, lesions were composed predominantly of CD4+ T cells, but in anti-CD4 mAb-treated mice, CD8+ T cells predominated. CONCLUSIONS. Although anti-CD4 mAb therapy of MRL/lpr mice eliminated autoimmune renal disease, autoantibody formation, and ocular inflammatory disease, it had a paradoxic effect on lacrimal gland lesions. Lacrimal gland lesions in the anti-CD4 mAb-treated mice were not decreased, but they had a different morphology and a different immunocytochemical profile.


This article has been cited by other articles:


Home page
 IOVSHome page
D. S. Vinay, J. D. Kim, T. Asai, B. K. Choi, and B. S. Kwon
Absence of 4 1BB Gene Function Exacerbates Lacrimal Gland Inflammation in Autoimmune-Prone MRL-Faslpr Mice
Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4608 - 4615.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
D. A. Jabs, R. A. Prendergast, E. M. Rorer, A. P. Hudson, and J. A. Whittum-Hudson
Cytokines in Autoimmune Lacrimal Gland Disease in MRL/MpJ Mice
Invest. Ophthalmol. Vis. Sci., October 1, 2001; 42(11): 2567 - 2571.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the Association for Research in Vision and Ophthalmology